DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Loi S, Giobbie-Hurder A, Gombos A. et al International Breast Cancer Study Group and the Breast International Group.
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.
Lancet Oncol 2019;
20 (03) 371-382
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.